|
Bali to Host 13th DCVMN Conference
Nusa Dua Bali, Indonesia, Oct 23, 2012 - (ACN Newswire) - Indonesian vaccine-maker Bio Farma is to host the 13th Annual General Meeting of Developing Countries Vaccine Manufacturers Network (DCVMN) in Bali, on October 31-November 2, 2012.
Bio Farma President Director Iskandar said on Tuesday that DCVMN is a strategic alliance among developing countries' vaccine manufacturers. Indonesia is a founding member of the vaccine network with a membership of 14 countries.
In total, there are currently 37 vaccine-making organizations and company members in the 14 DCVMN member countries.
Iskandar says, since its establishment in Bandung in 1999, the network has achieved numerous milestones particularly in providing quality and affordable vaccines accessible to developing countries populations.
The objective of 13th DCVMN General Meeting refers to the specific purpose of striving to increase availability and to improve the quality of vaccines produced in the developing countries. Bio Farma had assumed the position of first president of the group.
The network strives to promote the consistent and sustainable supply of quality vaccines at an affordable price and combat infectious diseases, especially those from the developing world, by strengthening the capacity of vaccine related product manufactures.
It also encourages research and development efforts to meet the need for vaccines, and fosters production and delivery of high quality vaccines and other health technologies effectively on a long-term basis for national immunization programs.
Bio Farma President Director Iskandar also says Bio Farma is the only vaccine manufacturer from Indonesia who strives to become a center for research and development of vaccines and serve as a partner to research new vaccines for developing countries.
Member countries of the DCVMN are Argentina, Bangladesh, Brazil, Cuba, Egypt, India, Indonesia, Iran, Mexico, Republic of China, Republic of Korea, South Africa, Thailand and Vietnam.
Member companies and organizations of DCVMN are Beijing Minhai Biotechnology, Bharat Biotech International Limited, Biological E. Limited, Bio-Manguinhos - Institute of Technology on Immunobiologicals, BioNet-Asia Co., Ltd., Cadila Pharmaceuticals Limited, Center for Genetic engineering and Biotechnology, Chengda Liaoning, and China National Biotec Group (CNBG).
Other members include EuBiologics, Finlay Institute, Haffkine, Hualan Bio, Incepta Ltd., Indian Immunologicals Limited, Institute of Vaccines and Medical Biologicals, Instituto Butantan, National Administration of Laboratories and Institute of Health ANLIS "Dr. Carlos G. Malbran."
Also represented are Panacea Biotec Ltd, Pasteur Institute of Iran, PT Bio Farma (Persero), Queen Saovabha Memorial Institute, Razi Vaccine & Serum Research Institute, Serum Institute of India Ltd, Sinergium, Sinovac Biotech Ltd., SK Chemicals, Biovac Institute, Company for Vaccine and Biological Production No.1 - Vabiotech, the Government Pharmaceutical Organization, the Holding Company for Biological Products & Vaccines (VACSERA), Tiantan, Walvax and Xiamen Innovax Biotech.
For more information, please visit www.13thdcvmn.com.
Contact:Aat Surya Safaat
General Manager, Corporate Business Development
Perum LKBN ANTARA - Indonesian News Agency
T: +62-21-3802-2383 ext 251
M: +62-811-225-2228
E: aat@antara.co.id
U: www.antaranews.com
Source: DCVMN
Sectors: BioTech
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network. |